| Not Yet Recruiting | A Phase 3 Clinical Study of QL2106 Injection NCT07511647 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Pat NCT07485764 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Not Yet Recruiting | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis NCT07474792 | Oruka Therapeutics, Inc. | Phase 2 |
| Suspended | Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis NCT06723171 | Io Therapeutics | Phase 2 |
| Recruiting | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis NCT07449702 | Oruka Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia NCT07373847 | Xiangya Hospital of Central South University | Phase 4 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque P NCT07326813 | InventisBio Co., Ltd | Phase 3 |
| Recruiting | A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In P NCT07357831 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis NCT07251998 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Recruiting | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis NCT07250802 | Takeda | Phase 3 |
| Recruiting | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis NCT07290569 | Oruka Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Partic NCT06979453 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Ps NCT07234591 | Usynova Pharmaceuticals Ltd. | N/A |
| Recruiting | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) NCT07116967 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis NCT07130604 | InventisBio Co., Ltd | Phase 3 |
| Recruiting | Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Sev NCT07039110 | AbbVie | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasi NCT07129382 | Chipscreen Biosciences, Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Pl NCT07158268 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Not Yet Recruiting | New Topical Treatment in Plaque Psoriasis NCT07113756 | Sohag University | N/A |
| Active Not Recruiting | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis NCT07090330 | Oruka Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis NCT06973291 | Takeda | Phase 3 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables NCT07024602 | Ascletis Pharma (China) Co., Limited | Phase 1 |
| Not Yet Recruiting | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy NCT06643260 | Can-Fite BioPharma | Phase 3 |
| Active Not Recruiting | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to I NCT06945107 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 3 |
| Active Not Recruiting | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis NCT06630559 | Celltrion | Phase 3 |
| Recruiting | A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis NCT07038720 | Usynova Pharmaceuticals Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With NCT06934226 | Janssen Research & Development, LLC | Phase 3 |
| Not Yet Recruiting | Understanding Participation Habits Among Plaque Psoriasis Patients NCT06338358 | Power Life Sciences Inc. | — |
| Recruiting | ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar NCT06997055 | Celltrion HealthCare France | — |
| Not Yet Recruiting | Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real) NCT06802848 | Chongqing Genrix Biopharmaceutical Co., Ltd | — |
| Recruiting | Modifying PEST for Psoriatic Arthritis Screening NCT06382051 | Novartis Pharmaceuticals | N/A |
| Not Yet Recruiting | Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Informatio NCT06790940 | Shanghai Yueyang Integrated Medicine Hospital | — |
| Active Not Recruiting | A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China NCT06512337 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis NCT06846541 | Alumis Inc | Phase 3 |
| Recruiting | Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study NCT06648772 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT06602219 | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Phase 2 |
| Active Not Recruiting | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis NCT06550076 | Takeda | Phase 3 |
| Not Yet Recruiting | Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index NCT06579976 | Shanghai Yueyang Integrated Medicine Hospital | — |
| Completed | Treatment of Moderate to Severe Plaque Psoriasis NCT06542614 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 NCT06588738 | Alumis Inc | Phase 3 |
| Active Not Recruiting | Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to NCT06640517 | Biocad | Phase 3 |
| Completed | To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis NCT07008547 | SPH-BIOCAD (HK) Limited | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis NCT06586112 | Alumis Inc | Phase 3 |
| Completed | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions. NCT07428941 | AI Labs Group S.L | — |
| Recruiting | Bimekizumab in Plaque Psoriasis NCT06336343 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Not Yet Recruiting | A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointme NCT06396013 | Beijing Hospital of Traditional Chinese Medicine | Phase 1 |
| Completed | Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin NCT07428915 | AI Labs Group S.L | — |
| Not Yet Recruiting | Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients NCT06370156 | Egymedicalpedia | — |
| Recruiting | A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis NCT06380907 | Zai Lab (Hong Kong), Ltd. | Phase 2 |
| Completed | A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis NCT06972888 | Accro Bioscience (Suzhou) Limited | Phase 2 |
| Completed | A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients NCT06357221 | Galderma R&D | Phase 4 |
| Active Not Recruiting | A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting NCT06488170 | Almirall, S.A. | — |
| Active Not Recruiting | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADV NCT06220604 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Role of Insulin Action in Psoriasis Pathogenesis NCT06242847 | Columbia University | — |
| Active Not Recruiting | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis NCT06143878 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis NCT06278350 | InventisBio Co., Ltd | Phase 2 |
| Recruiting | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect NCT06382987 | Bristol-Myers Squibb | — |
| Not Yet Recruiting | Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis NCT04239859 | Singapore General Hospital | Phase 4 |
| Completed | Bee Venom Phonophoresis on Mild to Moderate Localized Plaque Psoriasis on Knee Joint NCT06106230 | MTI University | N/A |
| Completed | A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT06176768 | Eli Lilly and Company | Phase 2 |
| Completed | Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis NCT05725057 | Artax Biopharma Inc | Phase 1 / Phase 2 |
| Completed | A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With NCT06122649 | Amgen | Phase 3 |
| Recruiting | Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis NCT06058546 | Tasly Pharmaceutical Group Co., Ltd | Phase 2 |
| Completed | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis D NCT06088043 | Takeda | Phase 3 |
| Completed | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis D NCT06108544 | Takeda | Phase 3 |
| Completed | Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity NCT07001904 | Tanta University | — |
| Active Not Recruiting | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis NCT06088199 | Amgen | Phase 3 |
| Recruiting | Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers NCT05994976 | Innovaderm Research Inc. | — |
| Active Not Recruiting | A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp NCT06095102 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis NCT06095115 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira® NCT06005532 | Mabscale, LLC | Phase 3 |
| Recruiting | A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported O NCT06030076 | Almirall, S.A. | — |
| Completed | A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With NCT06143371 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 |
| Active Not Recruiting | An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients Wit NCT06488664 | AO GENERIUM | Phase 3 |
| Completed | A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psor NCT05855967 | Eli Lilly and Company | Phase 4 |
| Completed | A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose NCT05811234 | Almirall, S.A. | — |
| Completed | Study to Assess the Reliability of PASI Scoring Using Digital-Based Images NCT05835843 | Innovaderm Research Inc. | — |
| Completed | A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis NCT05896527 | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Phase 2 |
| Active Not Recruiting | A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany NCT06104644 | Bristol-Myers Squibb | — |
| Completed | Clinical Study of Stage IV Psoriasis in Children With Geleli NCT05803187 | Bio-Thera Solutions | — |
| Completed | Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis NCT05763082 | Padagis LLC | Phase 3 |
| Active Not Recruiting | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Se NCT05565560 | Amgen | Phase 3 |
| Completed | The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis NCT05772520 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 2 |
| Active Not Recruiting | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis NCT05739435 | Alumis Inc | Phase 2 |
| Completed | The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Ada NCT05913817 | Jamp Pharma Corporation | — |
| Completed | Topical SGX302 for Mild-to-Moderate Psoriasis NCT05442190 | Soligenix | Phase 2 |
| Completed | Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients NCT05377944 | Bio-Thera Solutions | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis NCT05531682 | Huabo Biopharm Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis NCT05600036 | Alumis Inc | Phase 2 |
| Completed | A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or NCT05375955 | Pfizer | Phase 2 |
| Completed | Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Sever NCT05510063 | Samsung Bioepis Co., Ltd. | Phase 4 |
| Completed | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis NCT05272150 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis NCT05357755 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis NCT05364554 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoria NCT05509361 | Akeso | Phase 3 |
| Unknown | Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis NCT05072886 | Azora Therapeutics Australia Pty Ltd | Phase 1 |
| Completed | Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 NCT05332704 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis NCT05268016 | Meiji Pharma USA Inc. | Phase 2 |
| Completed | A Study of DLX105-DMP in Subjects With Plaque Psoriasis NCT04203433 | DelArrivo, Inc. | Phase 1 |
| Completed | A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis NCT05223868 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults NCT05203315 | Austin Institute for Clinical Research | Phase 3 |
| Recruiting | Psorcast Mobile Study NCT05621369 | Sage Bionetworks | — |
| Active Not Recruiting | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects NCT05172726 | Organon and Co | Phase 3 |
| Completed | Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live NCT04823247 | Almirall, S.A. | — |
| Unknown | Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis NCT05078567 | Microbio Co Ltd | N/A |
| Completed | A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis NCT05073315 | Amgen | Phase 3 |
| Unknown | Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine NCT05042635 | Shanghai Yueyang Integrated Medicine Hospital | N/A |
| Unknown | A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Pati NCT05036889 | Mindera Health | N/A |
| Completed | A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Pl NCT06808815 | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Completed | Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis. NCT05046899 | Biocool AB | N/A |
| Completed | A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis NCT05442788 | Huabo Biopharm Co., Ltd. | Phase 1 |
| Unknown | Evaluation of the Effect of Sulphur Mineral, Thermal Water on Skin Microbiome in Plaque Psoriasis, a Pilot Stu NCT05431959 | Szeged University | N/A |
| Completed | Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis NCT04728360 | Bio-Thera Solutions | Phase 3 |
| Completed | Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care NCT05891964 | Jinnah Postgraduate Medical Centre | Phase 4 |
| Completed | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis NCT04908514 | Aldeyra Therapeutics, Inc. | Phase 2 |
| Completed | A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) NCT04855721 | Aurigene Discovery Technologies Limited | Phase 2 |
| Completed | A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobe NCT05282771 | Sun Pharmaceutical Industries, Inc. | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Mod NCT04772079 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | Guselkumab Immunogenetics NCT04645355 | University of California, San Francisco | Phase 4 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) NCT04746911 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Unknown | Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study NCT04722094 | University of Siena | — |
| Completed | Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis NCT05650060 | Novartis Pharmaceuticals | — |
| Unknown | Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis NCT04571151 | Skin Sciences, PLLC | Phase 4 |
| Completed | Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment NCT05330936 | Pak Emirates Military Hospital | EARLY_Phase 1 |
| Completed | Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants Wi NCT04664153 | Pfizer | Phase 2 |
| Terminated | Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequa NCT04533737 | LEO Pharma | Phase 4 |
| Completed | A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquet NCT05108766 | Shenzhen Kangzhe Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis NCT04537689 | Singapore General Hospital | Phase 4 |
| Completed | An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinum NCT05368818 | Novartis Pharmaceuticals | — |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) NCT04655313 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis NCT04720105 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Completed | A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis NCT04607980 | Amgen | Phase 3 |
| Completed | A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinuma NCT04595409 | Bioeq GmbH | Phase 3 |
| Completed | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to S NCT04594928 | Galapagos NV | Phase 1 |
| Completed | A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis NCT04603027 | Evelo Biosciences, Inc. | Phase 2 |
| Completed | Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis NCT05344482 | Novartis Pharmaceuticals | — |
| Completed | Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Pati NCT04398732 | Pfizer | — |
| Completed | Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque P NCT04428411 | Pfizer | — |
| Completed | Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasi NCT04453137 | Alvotech Swiss AG | Phase 3 |
| Completed | A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) NCT04163016 | UCB Biopharma SRL | Phase 1 |
| Completed | A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis NCT04080206 | Therapeutics, Inc. | Phase 2 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis NCT04279119 | Arcutis Biotherapeutics, Inc. | Phase 1 |
| Terminated | A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Di NCT04237116 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis NCT04339595 | Almirall, S.A. | Phase 4 |
| Completed | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis NCT04128007 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis NCT04173637 | Akeso | Phase 2 |
| Completed | Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque P NCT04229836 | Almirall, S.A. | Phase 4 |
| Completed | A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a NCT04102007 | AbbVie | Phase 3 |
| Suspended | A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults NCT04121143 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical NCT04203693 | Almirall, S.A. | — |
| Recruiting | Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis NCT04036188 | Wright State University | EARLY_Phase 1 |
| Completed | Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are NCT04263610 | Almirall, S.A. | Phase 4 |
| Completed | A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Pa NCT04053881 | UCB Biopharma SRL | — |
| Completed | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) NCT04053387 | Organon and Co | Phase 3 |
| Completed | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis NCT04042103 | Organon and Co | Phase 2 |
| Completed | A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Ro NCT04031027 | Amgen | — |
| Completed | Autologous Natural Killer Cells in Subjects With Plaque Psoriasis NCT03894579 | NKGen Biotech, Inc. | Phase 1 |
| Completed | Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS NCT04018599 | Fresenius Kabi SwissBioSim GmbH | Phase 1 |
| Completed | A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Pso NCT03930186 | Amgen | Phase 3 |
| Completed | Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasi NCT03992261 | Mayne Pharma International Pty Ltd | Phase 4 |
| Completed | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) NCT03983980 | Organon and Co | Phase 3 |
| Unknown | Moving Cupping for Plaque Psoriasis: a Randomized Controlled Trial NCT03952676 | Shanghai Yueyang Integrated Medicine Hospital | N/A |
| Unknown | Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome NCT03953885 | Shanghai Yueyang Integrated Medicine Hospital | N/A |
| Unknown | Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine NCT03941431 | Shanghai Yueyang Integrated Medicine Hospital | Phase 2 |
| Completed | A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic D NCT03858634 | Genentech, Inc. | Phase 2 |
| Completed | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) NCT03956355 | Organon and Co | Phase 3 |
| Completed | Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis NCT03837743 | Durect | Phase 2 |
| Completed | Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis NCT03849404 | Alvotech Swiss AG | Phase 3 |
| Completed | Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis NCT03832738 | Akros Pharma Inc. | Phase 2 |
| Completed | Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Pl NCT03589885 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis NCT03764475 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis NCT03759197 | Therapeutics, Inc. | Phase 3 |
| Completed | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoria NCT03573323 | Eli Lilly and Company | Phase 4 |
| Completed | Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307) NCT03731052 | Therapeutics, Inc. | Phase 3 |
| Unknown | Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis NCT03817164 | Thync Global, Inc. | N/A |
| Completed | Pain Outcomes Following Intralesional Corticosteroid Injections NCT03630198 | Vanderbilt University Medical Center | Phase 4 |
| Completed | A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis NCT03614078 | PRCL Research Inc. | Phase 2 |
| Completed | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis NCT03638258 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis NCT03168256 | Can-Fite BioPharma | Phase 3 |
| Withdrawn | A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in NCT02993328 | Santalis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast NCT03442088 | University Hospitals Cleveland Medical Center | Phase 2 |
| Completed | Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color NCT03506477 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Completed | A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis NCT03364309 | Eli Lilly and Company | Phase 3 |
| Completed | An Open-Label Study to Assess Safety NCT03645499 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis NCT03591887 | Affibody | Phase 2 |
| Completed | A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis NCT04172233 | Akeso | Phase 1 / Phase 2 |
| Completed | The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients NCT03848871 | Derm Research, PLLC | Phase 4 |
| Terminated | AGN-242428 in the Treatment of Plaque Psoriasis NCT03339999 | Vitae Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis NCT03358290 | Akros Pharma Inc. | Phase 2 |
| Completed | Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis NCT03316781 | Shanghai Henlius Biotech | Phase 3 |
| Completed | Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque NCT03441789 | L.H. Kircik, M.D. | Phase 4 |
| Completed | A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects a NCT03210961 | Pfizer | Phase 1 |
| Completed | A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis NCT03000608 | Santalis Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis NCT03167515 | Ferndale Laboratories, Inc. | N/A |
| Completed | Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Pa NCT03055494 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis NCT03073200 | Eli Lilly and Company | Phase 3 |
| Completed | Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patien NCT03020199 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% NCT03212963 | Sun Pharmaceutical Industries Limited | Phase 4 |
| Completed | Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis NCT03066609 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203) NCT03065556 | Therapeutics, Inc. | Phase 2 |
| Withdrawn | Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spra NCT03298581 | Sun Pharmaceutical Industries Limited | Phase 2 |
| Completed | Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy NCT03000309 | Derm Research, PLLC | Phase 4 |
| Completed | Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasi NCT03018509 | Akros Pharma Inc. | Phase 1 |
| Completed | Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis NCT03005964 | AmDerma | Phase 2 |
| Completed | A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in NCT02886702 | Fougera Pharmaceuticals Inc. | Phase 3 |
| Completed | A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis NCT02899988 | Eli Lilly and Company | Phase 2 |
| Completed | An Open Label, Safety Study to Assess the Potential for Adrenal Suppression NCT02932878 | Sun Pharmaceutical Industries, Inc. | Phase 2 |
| Completed | Efficacy and Tolerability of Enstilar® in Daily Practice NCT02881346 | LEO Pharma | — |
| Completed | Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test NCT03004339 | DFB Soria, LLC | Phase 1 |
| Completed | Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis NCT02826603 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis NCT01815723 | Forward-Pharma GmbH | Phase 3 |
| Completed | A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310) NCT02742441 | Therapeutics, Inc. | Phase 3 |
| Completed | Real-life Evaluation of the Daivobet® Gel Applicator NCT02856542 | LEO Pharma | — |
| Completed | Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast NCT02749370 | Amgen | Phase 4 |
| Completed | Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients NCT02908347 | MetrioPharm AG | Phase 2 |
| Completed | A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. NCT02752776 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis NCT02749799 | Primus Pharmaceuticals | Phase 4 |
| Completed | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic T NCT02634801 | Eli Lilly and Company | Phase 3 |
| Unknown | ASIS for Enbrel in Plaque Psoriasis NCT02112097 | ASIS Corporation | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis NCT02514577 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis NCT02515097 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis NCT02561806 | Eli Lilly and Company | Phase 3 |
| Completed | Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Ps NCT02601469 | Sun Pharmaceutical Industries, Inc. | Phase 2 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis NCT02618759 | Sun Pharmaceutical Industries, Inc. | Phase 3 |
| Completed | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis NCT02462122 | Bausch Health Americas, Inc. | Phase 3 |
| Terminated | DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis NCT02527421 | Primus Pharmaceuticals | Phase 3 |
| Completed | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis NCT02462070 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis NCT02462083 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe NCT02513550 | Eli Lilly and Company | Phase 3 |
| Completed | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis NCT02489227 | Coherus Oncology, Inc. | Phase 3 |
| Completed | Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis NCT02494479 | Cellceutix Corporation | Phase 2 |
| Completed | A Long Term Safety Extension Study (CHS-0214-05) NCT02486939 | Coherus Oncology, Inc. | Phase 3 |
| Completed | Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis NCT02547714 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis NCT02412644 | Psoriasis Treatment Center of Central New Jersey | Phase 4 |
| Completed | Plaque Psoriasis Efficacy and Safety With Secukinumab NCT02409667 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study NCT02413229 | Sun Pharmaceutical Industries, Inc. | Phase 2 |
| Completed | A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine T NCT02486302 | Pfizer | — |
| Completed | Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Pl NCT02346240 | UCB Biopharma S.P.R.L. | Phase 3 |
| Completed | Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis NCT02340169 | Sun Pharmaceutical Industries, Inc. | Phase 4 |
| Completed | A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) NCT02368210 | Therapeutics, Inc. | Phase 3 |
| Unknown | Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis NCT02701205 | Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | Phase 3 |
| Completed | Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis NCT02098213 | Association Francaise pour la Recherche Thermale | N/A |
| Completed | Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With NCT02274792 | Amgen | Phase 4 |
| Completed | A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis NCT02367911 | Therapeutics, Inc. | Phase 3 |
| Completed | An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis NCT02326298 | UCB Biopharma S.P.R.L. | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Pl NCT02326272 | UCB Biopharma S.P.R.L. | Phase 3 |
| Completed | A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food NCT02310750 | Pfizer | Phase 1 |
| Terminated | Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis NCT02201524 | Pfizer | Phase 2 |
| Completed | A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psor NCT02435342 | Kineta Inc. | Phase 1 |
| Completed | Evaluate the Effect of Elimune Capsules NCT02251678 | Elorac, Inc. | Phase 1 |
| Completed | Plaque Psoriasis Study in Pediatric Subjects NCT02186665 | Galderma R&D | Phase 4 |
| Completed | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) NCT02134210 | Coherus Oncology, Inc. | Phase 3 |
| Completed | Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis NCT02129777 | Takeda | Phase 2 |
| Completed | Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis NCT02160665 | G & W Laboratories Inc. | Phase 3 |
| Terminated | Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis NCT02243787 | Covagen | Phase 1 / Phase 2 |
| Completed | Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis NCT02239666 | AstraZeneca | — |
| Withdrawn | TSO for Plaque Psoriasis NCT02011269 | Coronado Biosciences, Inc. | Phase 2 |
| Completed | Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis NCT02045277 | Bausch Health Americas, Inc. | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail P NCT02016482 | AbbVie | Phase 3 |
| Completed | DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis NCT02070965 | Primus Pharmaceuticals | Phase 2 |
| Terminated | Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis NCT02153840 | Guangdong Provincial Hospital of Traditional Chinese Medicine | N/A |
| Completed | Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy i NCT02192164 | Pfizer | — |
| Completed | Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients NCT01989429 | Maruho Europe Limited | Phase 3 |
| Completed | Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT01987843 | Tanabe Pharma Corporation | Phase 2 |
| Completed | Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis NCT01938599 | AmDerma | Phase 2 |
| Completed | Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With NCT01893567 | Galderma R&D | Phase 4 |
| Completed | Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With E NCT01875991 | Amgen | Phase 4 |
| Completed | A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) NCT01882647 | Therapeutics, Inc. | Phase 3 |
| Completed | A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis NCT01899729 | Idera Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304) NCT01871402 | Therapeutics, Inc. | Phase 3 |
| Completed | Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque NCT01710046 | Pfizer | Phase 2 |
| Completed | Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaq NCT01777191 | Eli Lilly and Company | Phase 3 |
| Completed | PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis NCT01766440 | Galderma R&D | Phase 4 |
| Completed | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in NCT01729754 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Dis NCT01768858 | AbbVie | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety NCT01722331 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | LAS41008 in Moderate to Severe Chronic Plaque Psoriasis NCT01726933 | Almirall, S.A. | Phase 3 |
| Completed | Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris NCT01707043 | Wake Forest University | Phase 4 |
| Completed | Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formu NCT01707368 | LEO Pharma | — |
| Terminated | Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis NCT01708629 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis NCT01646073 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Unknown | A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis NCT01558310 | Paul Steven Yamauchi, MD, PhD | Phase 4 |
| Completed | A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis NCT01680159 | Tanabe Pharma Corporation | Phase 3 |
| Completed | A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis NCT01634087 | Incyte Corporation | Phase 2 |
| Unknown | A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 NCT01670513 | Dow Pharmaceutical Sciences | Phase 1 / Phase 2 |
| Completed | A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis NCT01700985 | Therapeutics, Inc. | Phase 2 |
| Completed | Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression NCT01698333 | Therapeutics, Inc. | Phase 2 |
| Unknown | A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF NCT01566578 | Ennar Pharmaceuticals AF | Phase 1 |
| Completed | Adalimumab-psoriasis and Small Bowel Lesions NCT01556672 | Innovaderm Research Inc. | Phase 4 |
| Completed | A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries NCT01677598 | Janssen Research & Development, LLC | — |
| Completed | Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis NCT01483924 | ApoPharma | Phase 2 |
| Completed | A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Ps NCT01610596 | Therapeutics, Inc. | Phase 2 |
| Completed | Trial of CF101 to Treat Patients With Psoriasis NCT01265667 | Can-Fite BioPharma | Phase 2 / Phase 3 |
| Completed | Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis NCT01321164 | Medical University of Vienna | Phase 3 |
| Suspended | Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis NCT01279629 | Glenmark Farmacêutica Ltda | — |
| Completed | Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients NCT01301157 | Maruho Co., Ltd. | Phase 2 |
| Completed | A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate NCT01251614 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque P NCT01373567 | Piramal Enterprises Limited | Phase 4 |
| Completed | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe P NCT01232283 | Amgen | Phase 3 |
| Completed | A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psori NCT01235728 | Merck Sharp & Dohme LLC | Phase 1 |